| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03995641 Details | 2023-10-11 Interventional | 4 | 19 | Bupivacaine Triamcinolone A… Pelvic Organ Pr… Prolapse Postoperative P… Sacrospinous Li… Trigger Point I… | Never received appropriate formulation. - | |||
| NCT03190967 Details | 2023-10-11 Interventional | 1/2 | [2 Refs] | 12 | Temozolomide Trastuzumab Brain Neoplasms Breast Neoplasm… Neoplasm Metast… Brain Cancer Brain Metastasi… Breast Cancer | The phase II portion was never started as we could no longer get the drug from the
manufacturer. - | ||
| NCT03093831 Details | 2023-10-11 Interventional | 2 | 5 | Ibrutinib Lymphoma Lymphoma, B-Cel… Lymphoma, B-Cel… | Study did not meet the objectives and terminated early on 17 Jul 2020 due to poor recruitment - | |||
| NCT05788328 Details | 2023-10-10 Interventional | 1 | 16 | Dabigatran Rosuvastatin Ca… Overweight Healthy | The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data
from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated
transaminases in these Phase 1 studies as well as a Phase 2 study. - | |||
| NCT05728372 Details | 2023-10-10 Interventional | 1 | 0 | Copper Pembrolizumab Metastatic Mali… | withdrawn per PI - | |||
| NCT05085574 Details | 2023-10-10 Interventional | 2 | 0 | Celecoxib Famotidine COVID-19 Communicable Di… Coronavirus Inf… Infections Respiration Dis… Respiratory Tra… Virus Diseases 2019 Novel Coro… 2019 Novel Coro… 2019-nCoV Disea… 2019-nCoV Infec… COVID-19 Pandem… COVID-19 Virus … COVID-19 Virus … Coronavirus Dis… Covid19 SARS-CoV-2 Acut… SARS-CoV-2 Infe… | COVID environment, lack of site confidence to enroll subjects, sites not suited to study
procedures, decline of potential inpatient subjects at site - | |||
| NCT04907968 Details | 2023-10-10 Interventional | 1 | 31 | Carboplatin Carcinoma, Ovar… Ovarian Neoplas… Platinum-sensit… | Study Terminated by Sponsor - | |||
| NCT04700046 Details | 2023-10-10 Interventional | 3 | 0 | Mexiletine Myotonic Dystro… Myotonic Dystro… | Assessing novel alternative study designs and regulatory pathways - | |||
| NCT03403205 2017-004135-36 Details | 2023-10-10 Interventional | 3 | 214 | Choline Tetrathiomolybd… Hepatolenticula… Wilson Disease | Sponsor decision to terminate the program - | |||
| NCT05493501 2022-002674-93 Details | 2023-10-06 Interventional | 3 | 8 | Albumin-Bound P… Carboplatin Gemcitabine Osimertinib Paclitaxel Pemetrexed NSCLC | The study is being closed based on corporate changes at EQRx and is not related to any efficacy
or safety issues with aumolertinib. - | |||
| NCT04781647 Details | 2023-10-06 Interventional | 2 | 54 | Entecavir Interferon-alph… Interferons Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis, Chro… Chronic Hepatit… | Study ABI-H0731-203 was terminated early by the study Sponsor for strategic reasons to
prioritize research and development efforts on finite and curative HBV therapies. Study ABI-H0731-203 was terminated early by the study Sponsor for strategic reasons to prioritize research and development efforts on finite and curative HBV therapies. As a result, not all subjects completed Week 48 and some outcome measures were impacted. | |||
| NCT04768569 Details | 2023-10-06 Interventional | 2 | 24 | Zonisamide Deafness Hearing Loss Hearing Loss, N… | PINIHL Program terminated by DoD - | |||
| NCT04512911 Details | 2023-10-06 Interventional | 1 | 0 | Anti-Arrhythmia… Cardiomyopathie… Tachycardia Tachycardia, Ve… Ventricular Tac… | IRB approval expired 1/23/2023 and eclipsed the 6 month institutional window where study can be
reinitiated via progress report. No enrollment has taken place. - | |||
| NCT04419181 Details | 2023-10-06 Interventional | 2 | - | Ado-Trastuzumab… Carboplatin Docetaxel Maytansine Pertuzumab Trastuzumab Breast Neoplasm… HER2-positive B… | Change in the landscape of current treatment of early stage breast cancer. Larger clinical
trials answering similar questions are expected to result in the next few years. - | |||
| NCT03971734 Details | 2023-10-06 Interventional | 1 | 7 | Regadenoson Astrocytoma Glioblastoma Glioma Oligodendroglio… Anaplastic Astr… Anaplastic Olig… High Grade Glio… | Terminated [NCI decided to terminate ABTC Consortium due to NCI moving in different direction
for Brain Cancer] - | |||
| NCT05659459 Details | 2023-10-05 Interventional | 2 | - | Pioglitazone COVID-19 | Sponsor has financial issues - trial currently on hold - | |||
| NCT04393454 Details | 2023-10-05 Interventional | 2 | 6 | Sirolimus Neoplasms Cancer Metastatic Soli… Metastatic dMMR… Solid Tumor | Following discussion with the Cancer Center the PI elected to terminate the study. Completion
dates reflect date of this decision - | |||
| NCT04002037 Details | 2023-10-05 Interventional | 4 | 120 | Dexamethasone Triamcinolone Triamcinolone A… Triamcinolone d… Triamcinolone h… Tenosynovitis Trigger Finger … Trigger Finger | Preliminary analysis revealed no difference - | |||
| NCT02606136 2023-000321-80 Details | 2023-10-04 Interventional | 2 | 21 | Mitogens Muscular Dystro… Muscular Dystro… Duchenne Muscul… | Sponsor Decision - | |||
| NCT05456269 Details | 2023-10-03 Interventional | 1 | 0 | Bisantrene Cytarabine Decitabine Decitabine and … Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Acute Myeloid L… Chronic Myelomo… Higher Risk Mye… Recurrent Acute… Refractory Acut… | commercial reason - |